Paradigm Biocapital Advisors LP Makes New $9.08 Million Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Paradigm Biocapital Advisors LP acquired a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 276,439 shares of the biopharmaceutical company's stock, valued at approximately $9,084,000. Agios Pharmaceuticals makes up approximately 0.3% of Paradigm Biocapital Advisors LP's investment portfolio, making the stock its 28th biggest holding. Paradigm Biocapital Advisors LP owned approximately 0.48% of Agios Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in AGIO. Jefferies Financial Group Inc. acquired a new position in Agios Pharmaceuticals during the 4th quarter worth approximately $49,290,000. Adage Capital Partners GP L.L.C. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at approximately $9,957,000. Deutsche Bank AG increased its position in Agios Pharmaceuticals by 39.7% in the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after acquiring an additional 265,637 shares during the period. Casdin Capital LLC acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at approximately $8,215,000. Finally, Balyasny Asset Management L.P. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at approximately $8,151,000.

Insider Transactions at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. The trade was a 4.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock traded up $0.42 during trading hours on Monday, reaching $29.60. The company's stock had a trading volume of 155,481 shares, compared to its average volume of 695,666. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The company has a market capitalization of $1.71 billion, a P/E ratio of 2.61 and a beta of 0.77. The stock's fifty day simple moving average is $28.81 and its two-hundred day simple moving average is $36.57.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The firm had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective for the company. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, May 10th. Finally, Scotiabank reduced their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.